-
Zhang Yang: Antiphospholipid syndrome and cardiovascular disease
Time of Update: 2020-12-15
study, published in the journal HEART in 2018 to explore the relationship between aPL and thrombosis events in IE patients, showed that the risk of cerebral embolism in the aCL-lgM-positive group was significantly higher than in the aCL-lgM-negative group.
-
The risk of coronary heart disease for chronic inflammatory diseases varied widely, with the highest risk of systemic lupus erythematosus, and psoriasis and inflammatory bowel disease were not associated with an increased risk of cardiovascular disease
Time of Update: 2020-12-15
Current AHA/ACC guidelines list three chronic inflammatory diseases as risk factors for atherosclerotic cardiovascular disease: rheumatoid arthritis, psoriasis, and HIV infection. , however, Dr. Arjun
-
Dupixent has been approved in the European Union for special dermatitis in children
Time of Update: 2020-12-15
the approval was based on data from dupilumab's key Phase III efficacy and safety studies of dupilumab combined local corticosteroids (TCS), the average improvement rate for patients in the Dupixent group was 82 percent, compared with 49 percent for patients who used TCS alone.
-
European Commission approves TREMFYA ® (guselkumab) for the treatment of active psoriasis arthritis (PsA)
Time of Update: 2020-12-14
Johnson and Johnson Pharmaceuticals announced today that the European Commission (EC) has approved TREMFYA® (guselkumab) for the treatment of adult patients with active psoriasis arthritis (PsA), who are not responsive or insufficiable to previous treatments for anti-disease rheumatoid drugs (DMARD).
-
Cell Metabolism: Significant progress! Chi Hongbo's team revealed metabolic mechanisms that regulate Treg cells or provide new targets for autoimmune disease therapy
Time of Update: 2020-12-14
addition, the authors identified specific catalytic effects of Fntb on mTORC1 activity and ICOS expression to maintain eTreg cells, while Pggt1b mediates TCR activation and Rac signal conduction eTreg cell differentiation.
-
Lancet Neurology: Safety and immunogenicity of α-synaptic nuclear protein active immunotherapy PD01A in patients with Parkinson's disease: a randomized, single-blind, Phase 1 trial
Time of Update: 2020-12-14
patients were randomly assigned (1:1) to receive 4 subsute immunizations using computer-generated sequences of different sizes, of which 15 or 75 μg PD01A was injected into the upper arm, initially for 52 weeks, followed by 39 weeks.
-
Lancet pheumatol: Under the skin to be treated with Anifrolumab systemic lupus erythematosus
Time of Update: 2020-12-13
Given that patients may find it more convenient to administer drugs under the skin than intravenously, the researchers evaluated the pharmacogenetics, efficacy, safety and efficacy of patients treating SLE, active dermatology, and high-type interferon genetic characteristics with under-skin injections.
-
JCEM: The gut microbiome of polycystic ovary syndrome and its relationship to metabolic symptoms
Time of Update: 2020-12-12
their study showed that significant changes in microbes in the intestines of women with polycystic ovary syndrome were associated with their metabolic health in late reproductive stages.
" results showed no significant differences in the gut microbiome between women with polycystic ovary syndrome and healthy women in the late stages of childbirth.
-
Study analyzes "invasion map" of rice plague bacteria attacking rice immune response
Time of Update: 2020-12-11
Protein kinase MoOsm1 phosphate/dephosphate monitoring rice reactive oxygen, control their own pathogenicity, maintain the molecular mechanism of semi-living nutrient growth, thus revealing the rice plague bacteria first "attack the city slightly", and then "war-raising" cunning strategy.
-
Am J Clin Nutr: An anti-inflammatory diet reduces disease activity in patients with rheumatoid arthritis
Time of Update: 2020-12-11
study included 50 RA patients who were randomly assigned to an interventional diet that included a recommended combination of anti-inflammatory foods, or a controlled diet similar to the average Swedish dietary intake, for a period of 10 weeks.
-
Blood Advances: Biomarkers predict symptoms of vascular damage in children after contracting new coronary pneumonia
Time of Update: 2020-12-11
December 9, 2020 // -- Researchers at Children's Hospital of Philadelphia (CHOP) found elevated levels of biomarkers associated with vascular damage in children infected with SARS-CoV-2, even if the children had little or no COVID-19 symptoms.
-
elife: How lung bacteria fight pneumonia
Time of Update: 2020-12-11
December 9, 2020 // -- A recent study revealed how lung bacteria prevent infections that invade pathogens.
study in mice showed that Lactobacillus in the lungs provided a barrier against Streptococcus pneumoniae after infection and treatment.
-
The Lancet Respiratory Medicine: A New Mechanism for The Occurrence of Fatal Lung Disease
Time of Update: 2020-12-11
() Source: Research sheds new light on cause of deadly lung disease Original source: Anna Duckworth et al, Telomere length and risk of idiopathic pulmonary fibrosis and chronic ability pulmonary disease: a mendelian random study, The Lancet Carey Medicine (2020).
-
Asaan Pharma Bcl-2 inhibitor APG-2575 won two IB/ ...
Time of Update: 2020-11-30
The Phase Ib/II clinical trial of WM as a single drug or joint Ibrutinib/Rituximab treatment is a global multi-center study involving the United States, Australia and China.
-
CTI: In-depth disclosure of the immune response characteristics of COVID-19 patients
Time of Update: 2020-11-29
, there was little difference in T-cell response in the blood of severe COVID-19 patients compared to healthy volunteers.
-
Sci Signaling: Multiple sclerosis drugs may aggravate the condition
Time of Update: 2020-11-29
November 16, 2020 // -- A new study from the University of Virginia School of Medicine suggests that a drug promising to treat multiple sclerosis could actually worsen the disease.
-
Cell Metabol: Two key events that can turn normal cells into cancer cells
Time of Update: 2020-11-29
November 16, 2020 // -- In a recent study published in the international journal Cell Metabolism, scientists from the University of Pennsylvania's Perelman School of Medicine and other institutions sa
-
Nat Microbiol: Two special signal molecules that compete or work together to control the growth and behavior of bacteria
Time of Update: 2020-11-29
16, 2020 // -- In a recent study published in the international journal Nature Microbiology, scientists from the University of Basel and others found two signaling molecules that can control the growt
-
PNAS: Scientists are expected to use the blistering oral disease virus to reveal the molecular mechanisms by which SARS-CoV-2 blocks the immune response of host bodies
Time of Update: 2020-11-29
Ren said that while SARS-CoV-2 is a completely new virus that the world is working on, it uses a strategy similar to VSV to target the same host factors, which may give researchers a deeper understanding of the virus, and after years of research on influenza A viruses and VSVsV, finding such small differences at cellular levels may give scientists a more comprehensive understanding of the disease epidemic caused by COVID-19.
-
Science Sub-Journal: Total survival rate up to 80%! CRIS...
Time of Update: 2020-11-29
studies have shown that a single intra-brain injection of CRISPR LNP (sgPLK1-cLNP) in invasive in-place glioblastoma in mice can increase the gene editing rate in the body by about 70%, significantly reduce tumor growth, extend the medium survival by about 50%, and increase the overall survival rate to 30% (figure H below).
